BPTES appeared to re-sensitize otherwise resistant melanoma cells to BRAF inhibition, as well as cisplatin-resistant ovarian and breast cancer cells to chemotherapy, owing to their reliance on the glutamine metabolism [115,116,117,127]. Here, BRAF is linked to melanoma.